IP Landscape Analysis: A Key to Strengthening Your Competitive Edge
Mar 31st, 2020 by Michael Dilworth | Recent News & Articles |
Understand what is IP Landscape Analysis, its benefits and how contributes to a business product development.
Mar 31st, 2020 by Michael Dilworth | Recent News & Articles | Share
Understand what is IP Landscape Analysis, its benefits and how contributes to a business product development.
Mar 31st, 2020 by Michael Dilworth | Recent News & Articles | Share
Learn 10 essential steps you can take to protect your brand in today’s business world.
Mar 31st, 2020 by Michael Dilworth | Recent News & Articles | Share
A company’s brand is one of its most valuable strategic assets and one of its most visible ones. Learn the importance of the scope and power of your brand and how to move toward success.
Mar 31st, 2020 by Michael Dilworth | Recent News & Articles | Share
Learn how to assess your firm’s readiness to identify and exploit its IP capabilities using a set of questions related to Intellectual Property.
Nov 21st, 2019 by William Reid | Recent News & Articles | Share
Thanksgiving is the best family holiday. It is stocked full of tradition: family, laughing, turkey dinner, football, and more turkey; while at the same serving as a catalog for memories that mark the progression of our lives. Fortunately, I was always able to get at least one of the Turkey legs, which you could pick up like fried chicken and dive-in without concern for cutlery rules, dripping juice or falling bits of skin or meat (these were the dog’s responsibility). Imagine the shock when a few months ago I stumbled on U.S. Patent No. 10,327,596 for a turkey leg holder.
Oct 25th, 2019 by William Reid | Patent Related Court Rulings | Recent News & Articles | Share
In OSI Pharmaceuticals, LLC v. Apotex Inc.[1] the Federal Circuit reversed the Patent Trial and Appeal Board’s inter partes review decision that claims 44-46 and 53 of OSI’s patent U.S. 6,900,221 (‘221 Patent) were unpatentable as obvious.[2] It is a noteworthy case because it squarely addresses obviousness and reasonable expectation […]
Jul 18th, 2019 by William Reid | Patent Trends & Activity | Recent News & Articles | Share
Carbon Dioxide injection has been used effectively for enhanced oil recovery from reservoirs, since at high pressures it forms a miscible mixture with oil, increasing the volume of the oil, and allowing it to dislodge additional material from the rock as it pushes through the formation.[1] CO2 injection is often used in a process known as water alternated with gas (WAG), where the gas and water are alternately injected into the well, thereby mitigating the tendency of the lower density gas to migrate to the top of the reservoir and bypass other sections.[2] Interest in CO2 injection continues, not simply in conventional oil reservoirs, but in unconventional reservoirs as well.[3] Not surprisingly, aspects of CO2 injection find their way into patent claims.
May 9th, 2019 by Ben Lehberger | News | Recent News & Articles | Share
Trade secret law provides protection for information that its owner takes reasonable measures to keep secret and that derives independent economic value from not being generally known or readily ascertainable. If a trade secret is misappropriated by another, the owner may be entitled to damages, an injunction preventing further use or disclosure of the trade secret, and in some cases the recovery of attorneys’ fees.
May 7th, 2019 by William Reid | News | Patent Related Court Rulings | Recent News & Articles | Share
In Endo Pharmaceuticals Inc. v. Teva[1] the Federal Circuit has further clarified the patent eligibility of treatment methods which include natural elements. The Opinion, which includes comparisons with other cases such as Vanda[2], CellzDirect[3] and Ariosa Diagnostics[4], leaves one crafting such claims on ground that is fairly firm.
Feb 7th, 2019 by William Reid | Patent Related Court Rulings | Patent Trends & Activity | Recent News & Articles | Share
In Amerigen Pharmaceuticals Limited v. UCB Pharma GMBH, 2017-2596 (Fed. Cir. January 11, 2019), the Federal Circuit upheld the Board’s IPR finding that claims 1-5 and 21-24 of UCB’s U.S. Patent 6,868,650 were not obvious.[1] The patent claims cover Toviaz® (Fesoterodine), an antimuscarinic drug to treat urinary incontinence.[2] Judge Lourie included a remark […]
This website uses cookies to improve functionality and performance. If you continue browsing the site, you are giving implied consent to the use of cookies and tracking on this website.